BLUE BELL, PA --- Wingspan Technology announced the release of SiteZone, a solution for collaboration between sponsors, CROs, and site personnel. The cloud-based product provides one location for collecting and tracking investigator content.
Designed for the average internet user, SiteZone features an intuitive user interface, requiring little or no training at the site level. Investigators can access and sign certain eTMF documents, as well as upload documents that originate on site. Administrators can track the progress of individual sites and easily view missing documents.
“Clinical trials often require a global reach. SiteZone improves the overall workflow and saves time and resources throughout the course of a trial,” Wingspan CEO Troy Deck said. “We are offering Sponsors and CROs a way to quicken study startup, reduce costs for paper and site visits, and improve overall efficiency.”
SiteZone is comparable to site portal solutions. It features the components needed to manage user access, support site users, and expedite the collection and delivery of documents. Personal credentials are created and managed by Wingspan, taking the burden away from sponsors, and allowing site personnel to use SiteZone across trials and sponsors. SiteZone’s electronic signature feature makes it easy for sites to sign and submit documents and also eliminates the need for on-site storage of many paper documents.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.